Cue Biopharma
CUE
54 hedge funds and large institutions have $12.8M invested in Cue Biopharma in 2024 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 5 reducing their positions, and 7 closing their positions.
488% more call options, than puts
Call options by funds: $47K | Put options by funds: $8K
260% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 5
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
22% more capital invested
Capital invested by funds: $10.5M → $12.8M (+$2.28M)
8% more funds holding
Funds holding: 50 → 54 (+4)
0.33% less ownership
Funds ownership: 0.95% → 0.62% (-0.33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$153K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$107K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$87.6K |
| 4 |
BlackRock
New York
|
+$85.1K |
| 5 |
HF
HRT Financial
New York
|
+$61.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
-$1.82M |
| 2 |
Millennium Management
New York
|
-$363K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$178K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$19.9K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$18.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Fidelity Investments
Boston,
Massachusetts
| $105 | -$263 | -7 | -70% |
|
|
PD
52
Point72 (DIFC)
Dubai,
United Arab Emirates
| $72 | – | – | – |
|
|
SFGP
53
Stonebridge Financial Group (Pennsylvania)
Wormleysburg,
Pennsylvania
| $68 | +$75 | +2 | New |
|
54
Citigroup
New York
| $47 | – | – | – |
|
|
SS
55
SBI Securities
Tokyo,
Japan
| $1 | – | – | – |
|
|
SPC
56
Slate Path Capital
New York
| – | -$1.82M | -80,082 | Closed |
|
|
57
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$18.7K | -822 | Closed |
|
58
Dimensional Fund Advisors
Austin,
Texas
| – | -$10.9K | -486 | Closed |
|
|
LCGC
59
Legacy Capital Group California
Los Gatos,
California
| – | -$7.57K | -333 | Closed |
|
|
CFM
60
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$6.81K | -300 | Closed |
|
|
HI
61
Harbour Investments
Madison,
Wisconsin
| – | -$332 | -15 | Closed |
|
|
AAP
62
Arax Advisory Partners
Denver,
Colorado
| – | -$163 | -7 | Closed |
|
CUE Hedge Fund Activity: Q4 2024 in Review
54 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2024, worth a combined $12.8M — up 22% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CUE positions and 7 closed out — a net gain of 4 holders — while 18 added to existing stakes and 5 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $153K. The largest seller was Slate Path Capital, exiting entirely with an estimated $1.82M sold.
- 54 institutional investors held Cue Biopharma (CUE) as of Q4 2024, up from 50 in Q3 2024.
- Funds reported $12.8M of Cue Biopharma stock for Q4 2024, up 22% quarter-over-quarter.
- 11 funds opened new Cue Biopharma positions in Q4 2024 and 7 closed out, a net change of +4 holders.
- The largest Cue Biopharma buyer in Q4 2024 was Geode Capital Management, an estimated $153K added.
- The largest Cue Biopharma seller in Q4 2024 was Slate Path Capital, an estimated $1.82M sold.
Based on aggregated 13F filings for Q4 2024.